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Abstract
Background: Sulphadoxine-pyrimethamine (SP) has been and is currently used for treatment of
uncomplicated  Plasmodium falciparum malaria in many African countries. Nevertheless, the
response of parasites to SP treatment has shown significant variation between individuals.
Methods: The genes for dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) were
used as markers, to investigate parasite resistance to SP in 141 children aged less than 5 years.
Parasite DNA was extracted by Chelex method from blood samples collected and preserved on
filter papers. Subsequently, polymerase chain reaction (PCR) and restriction fragment length
polymorphism (PCR-RFLP) were applied to detect the SP resistance-associated point mutations on
dhfr and dhps. Commonly reported point mutations at codons 51, 59, 108 and 164 in the dhfr and
codons 437, 540 and 581 in the dhps domains were examined.
Results: Children infected with parasites harbouring a range of single to quintuple dhfr/dhps
mutations were erratically cured with SP. However, the quintuple dhfr/dhps mutant genotypes were
mostly associated with treatment failures. High proportion of SP resistance-associated point
mutations was detected in this study but the adequate clinical response (89.4%) observed clinically
at day 14 of follow up reflects the role of semi-immunity protection and parasite clearance in the
population.
Conclusion: In monitoring drug resistance to SP, concurrent studies on possible confounding
factors pertaining to development of resistance in falciparum malaria should be considered. The SP
resistance potential detected in this study, cautions on its useful therapeutic life as an interim first-
line drug against malaria in Tanzania and other malaria-endemic countries.
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Background
Human malaria is caused by an Apicomlexan parasite of
the genus Plasmodium. Four species are known to cause
human malaria namely, Plasmodium falciparum, Plasmo-
dium vivax,  Plasmodium ovale and  Plasmodium malariae.
Nevertheless, P. falciparum has been found to be the most
lethal of all human malaria parasites. This parasite causes
epidemics in malaria-endemic countries, resulting in large
numbers of deaths. Widespread chloroquine resistance
has forced many countries to use alternative drugs as anti-
malarials against falciparum malaria, such as the combi-
nation of sulphadoxine and pyrimethamine (SP).
However, the parasite has been observed to develop resist-
ance to this drug combination associated with point
mutations in the genes for the enzymes involved in the
obligatory parasite-folate biosynthesis pathway. Such
mutations lead to the lowering of the drug binding affin-
ity to the parasite enzymes [1-5]. Resistance to pyrimeth-
amine is attributed to mutations in the gene for the
parasite enzyme dihydrofolate reductase (dhfr), whereas
sulphadoxine resistance is associated with mutations in
the gene for the parasite enzyme dihydropteroate syn-
thetase (dhps). The increased level of resistance has been
found to be associated with increased numbers of muta-
tions in the genes for these two enzymes. Studies [6] have
shown that multiple mutations in the genes for both
enzymes result in exceedingly high SP treatment failure.
Detection of these mutations in field isolates has been
proposed as an alternative strategy for rapid screening of
antifolate drug resistance [7-12].
In Tanzania, due to high resistance that developed against
the previously effective, safe and relatively cheap antima-
rial drug, chloroquine, SP was introduced as the first-line
drug against malaria by August, 2001. Unfortunately, the
change of policy to SP by the government has been chal-
lenged by the previously reported low [13] but fast spread-
ing levels of resistant parasite strains against the drug [14].
SP resistance has been reported in variable magnitudes
across the country [15-17]. Surveillance for these anti-
folate-resistant parasites in the field is still required to dis-
suade its spread over wide areas and possibly suggest
effective implementation of new drug policy in Tanzania.
The present study was thus carried out during the period
of January 2002 to August 2004 to evaluate the frequency
of point mutations in dhfr and dhps among P. falciparum
isolates from children of Mlimba division of Kilomero
district of Tanzania. This could give a picture of the level
of drug pressure in the field from the time when SP was
introduced as an interim first-line drug for malaria treat-
ment in the country. Since there are currently, various
drug combinations on trial for treatment of uncompli-
cated falciparum malaria [18,19], the anticipation was to
obtain findings which would give information on the cur-
rent frequencies of SP resistant P. falciparum strains and
probably give advice to policy makers for opting to other
new effective, cheap and safe antimalarial drug combina-
tions.
Materials and methods
Study area
The study was conducted at Ifakara Health Research and
Development Center (IHRDC) situated in Ifakara Town of
Kilombero District, Morogoro, Tanzania. Samples were
collected during the period of January to August 2002
from Mlimba, an area about 150 km from IHRDC along
Kilombero River where malaria is endemic with perennial
transmission. The area is among nine sentinel sites for
National Malaria Control Programme since 1997 and its
human population dynamics is being closely monitored
on a monthly basis by the Ifakara Centre Demographic
Surveillance System (IC-DSS) since 1996. Recruitment of
patients and sample collection was done by the research
team at Mlimba Health Centre.
Study subjects
The ethical clearance was obtained from both National
Institute for Medical Research (NIMR) and IHRDC Insti-
tutional Ethics Committee authorities. Parents or guardi-
ans of participating children accepted and gave informed
consent for participation in the study. About 172 patients
of both sexes with acute uncomplicated falciparum
malaria and aged 6 – 69 months (< 5 years) were initially
recruited in this study. However 31 (18%) of the recruited
patients either were excluded from the study due to failure
to comply with criteria for participating in the study or
were lost during follow up.
Sample collection
Blood samples for parasite genotyping were collected on
filter paper (3 MM Whatman), labelled and identified,
and kept in a dry clean container with desiccant for a min-
imum of three hours to dry. Dry filter paper blood sam-
ples were stored at room temperature until when needed
for further analyses. The follow-up samples were obtained
at days 3, 7 and day 14 after SP treatment. Additional fol-
low-ups were done at any other day if the child was
unwell. During all these visits, finger-prick blood was
obtained for microscopy and later molecular analysis.
Extraction of parasite DNA
P. falciparum genomic DNA was extracted from blood col-
lected on 3 MM Whatmann filter paper by Chelex method
as previously described [20]. The extracted DNA from
each sample was used immediately for PCR and any
remaining portion was stored at -20°C in appropriately
labelled storage tubes.Malaria Journal 2006, 5:94 http://www.malariajournal.com/content/5/1/94
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Genotyping of parasite genomic DNA
Sample analysis was based on the standardised polymer-
ase chain reaction and restriction fragment length poly-
morphism. For amplification of the dhfr and dhps coding
regions, a nested PCR protocol was adopted followed by
RFLP. The regions of the dhfr and dhps genes surrounding
the polymorphisms of interest in dhfr 51, 59, 108 and 164
and  dhps  437, 540 and 581 codons were analysed as
described in detail elsewhere [7,21,22].
Amplification of parasite DNA by PCR
In this multiplex parasite DNA amplification of the para-
site genomic DNA, two primer pairs M1/M5 and R2 + R/
were used as forward and reverse primers in primary (nest
I) PCR reaction for the dhfr and dhps domains respectively.
In secondary (nest II) PCR reaction M3 + F/ and F + M4
were used as forward and reverse primers to amplify the
four regions on dhfr where the point mutation is antici-
pated to occur [20]. On the other hand, K +K/ and L + L/
primers were used to amplify regions on the dhps gene
where resistance-associated mutations are said to occur
[7]. The details of primer sequences, annealing tempera-
tures and controls are shown in Table 1. In both nest I and
nest II PCR, reaction volumes ranged from 20 µl to 30 µl.
The final concentration of each reagent was 1× PCR reac-
tion buffer (10× PCR buffer – MgCl2, Invitrogen), 1.5 mM
MgCl2, 125 µM dNTP (Promega, Madison, WI, USA), 250
nM primers (QIAGEN, Operon) and 0.02 U/µl Taq
Polymerase (Invitrogen). The master mix was prepared in
a 1.5 ml reaction tube with Molecular biology PCR water
(Sigma) as a diluent and aliquots made in PCR tubes (0.2
ml size). To each PCR tube, 5 µl of DNA was added in pri-
mary reaction and 2 µl was re-amplified in the nested PCR
reaction. The known purified genomic DNA from HB3,
3D7, W2, K1, T9/96, FCR3 and V1/S laboratory parasite
clones were used as positive controls and NT (No tem-
plate) was included as negative control. PCR was per-
formed in a Programmable Thermo Controller, (PTC-100
(TM) MJ Research, Inc., Watertown, MA, USA). Samples
with no detectable PCR products were re-examined at
least twice starting from the DNA preparation before were
declared negative.
Restriction enzyme digestion
Site-specific restriction enzymes were used to digest the
PCR amplicons. Seven different restriction enzymes were
used in this study (Table 1), namely TSP509I, XmnI,AluI,
DraI (dhfr domain) and AvaII, FokI, BstUI (dhps domain)
enzymes, respectively. Essentially, 8 µl of PCR products
were incubated with restriction enzymes (New England
Biolabs, Beverly, MA, USA) according to manufacturer's
protocol in 25 µl final reaction volume. The dhfr and dhps
variants were identified as previously described [7,21,23].
Gel electrophoresis
Nested PCR amplicons were electrophoresed on 2% agar-
ose gels before subsequent restriction fragment length
polymorphism analysis. Electrophoresis of restriction
digests was done on 10% polyacrylamide gel (PAA) as
described by Sambrook et al. [24] at a constant voltage of
11.25 v/cm gel for 2.30 hours, stained with ethidium bro-
mide, visualized under UV light, photographed and elec-
tronically stored.
Statistical analysis
Data were analysed using the EPI Info Version 6.04 epide-
miological software (Centres for Disease Control and Pre-
vention, Atlanta, GA, USA). This made it possible to
estimate the frequency of point mutations on dhfr and
dhps  responsible for parasite resistance against SP thus
determining the prevalence of these mutations. The prev-
alence of each point mutation was calculated as the per-
centage of baseline (D0) samples containing point
mutation at the particular codon on dhfr and dhps, respec-
tively. Fragment sizes were compared with known restric-
tion fragments (band sizes) obtained in previous studies
with reference to 1 Kb DNA marker [21,25].
Results
Treatment outcomes
From clinical evaluation (clinical data provided by
IHRDC), a total of 172 children with acute uncomplicated
malaria were recruited into the study and treated with SP.
Out of these recruited patients, 141 (82%) successfully
completed the study. Data from 31 (18%) patients who
could not complete the 14 days follow-up were excluded
from analysis. Of patients who completed the study suc-
cessfully, treatment failures were depicted in 15 (10.6%)
patients comprising of 6.7% early and 3.9% late treatment
failures, respectively. Adequate clinical response occurred
in 126 (89.4%) of patients. Consequently, molecular
analysis was performed on 141 samples from patients
who completed the study.
PCR amplification of dhfr and dhps
Different primers were used to amplify regions in dhfr and
dhps containing various point mutations associated with
resistance to SP, thus different DNA fragments with differ-
ent band sizes were obtained (Figure 1). The fragment
sizes were estimated as previously described elsewhere
[21]. F + M4 amplification produced DNA amplicons of
about 326 bp (Figure 1a) while DNA amplicons of
approximately 522 bp band size were obtained following
DNA amplification by M3 + F/ primers (Figure 1b). PCR
amplification using K + K/ (Figure 1c) and L + L/ primers
(Figure 1d) produced fragments of 438 and 161 bp,
respectively on 2% agarose gel. Of 141 samples analysed,
120 (85.1%), 136 (96.5%), 132 (93.6%) and 133M
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Table 1: Polymorphic genes investigated, mutation sites, primers and primer sequences, PCR reaction conditions, restriction enzymes and control DNA used in this study
Gene Mutation Primers Primer Sequences PCR conditions Enzyme 
digest
Control DNA
DHFR Primary M1
M5
5' TTTATGATGGAACAAGTCTGC3'
5' AGTATATACATCGCTAACAGA3'
94°C-3 min, 94°C-1 min, 50°C-2 min, 72°C-2 min, ×40, 72°C-10 min, 4°C-hold
DHFR Nested N51I M3
F/
5'TTTATGATGGAACAAGTCTGCGACGTT3'
5'AAATTCTTGATAAACAACGGAACCTttTA3'
94°C-2 min, 94°C-1 min, 45°C-1 min, 72°C-2 min, ×35, 72°C-10 min, 4°C-hold TSP5091 (+) K1
C59R F
M4
5'GAAATGTAATTCCCTAGATATGGAATATT3'
5'TTAATTTCCCAAGTAAAACTATTAGAGCTTC3'
94°C-2 min, 94°C-1 min, 45°C-1 min, 72°C-2 min, ×35, 72°C-10 min, 4°C-hold XmnI (+) T9/96
S108N F
M4
5'GAAATGTAATTCCCTAGATATGGAATATT3'
5'TTAATTTCCCAAGTAAAACTATTAGAGCTTC3'
94°C-2 min, 94°C-1 min, 45°C-1 min, 72°C-2 min, ×35, 72°C-10 min, 4°C-hold Alu1 (+) HB3
(+) T9/96
(+) FCR3
I164L M3
F/
5'TTTATGATGGAACAAGTCTGCGACGTT3'
5'AAATTCTTGATAAACAACGGAACCTTTTA3'
94°C-2 min, 94°C-1 min, 45°C-1 min, 72°C-2 min, ×35, 72°C-10 min, 4°C-hold DraI (+) V1/S (+) HB3
(+) DD2
DHPS Primary R2
R/
5' AACCTAAACGTGCTGTTCAA3'
5' AATTGTGTGATTTGTCCACAA3'
94°C-3 min, 94°C-1 min, 50°C-2 min, 72°C-2 min, ×40, 72°C-10 min, 4°C-hold
DHPS Nested A437G K
K/
5'TGCTAGTGTTATAGATATAGGATGAGcATC3'
5'CTATAACGAGGTATTGCATTTAATGCAAGAA3'
94°C-2 min, 94°C-1 min, 45°C-1 min, 72°C-2 min, ×35, 72°C-10 min, 4°C-hold AvaII (+) K1
(+) FCR3
K540D K
K/
5'TGCTAGTGTTATAGATATAGGATGAGCATC3'
5'CTATAACGAGGTATTGCATTTAATGCAAGAA3'
94°C-2 min, 94°C-1 min, 45°C-1 min, 72°C-2 min, ×35, 72°C-10 min, 4°C-hold FokI( + )  T N - 1
(+) VIS
(+) W2
A581G L
L/
5'ATAGGATACTATTTGATATTGGACCAGGATTCG3'
5'TATTACAACATTTTGATCATTCGCGCAACCGG3'
94°C-2 min, 94°C-1 min, 45°C-1 min, 72°C-2 min, ×35, 72°C-10 min, 4°C-hold BstUI (+) K1
(+) DD2
Source: Duraisingh et al. [21]; Foley et al. [48]Malaria Journal 2006, 5:94 http://www.malariajournal.com/content/5/1/94
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(94.3%) were successfully amplified using M3+ F/, F +
M4, K + K/ and L +L/ primers, respectively.
RFLP analysis
Figure 2 depicts representative PAA gels of the restriction
digests used to detect the fragment patterns corresponding
to the different variants at each codon on the dhfr and dhps
domains. PCR amplification of dhfr with the primers F +
M4 yields a PCR product sized 326 bp of the codon 108.
The restriction enzyme AluI was used specifically to cut
fragments discriminating the two alternative forms, wild-
type (180 and 118 bp) and mutant (299 plus 27 bp) at
that codon. The wild type indicates presence of serine
(Ser) in the amino acid sequence of the enzyme system
while the mutant form of the gene indicates the substitu-
tion by asparagine (Asn). Restriction digestion of the
same PCR fragment with XmnI was used to distinguish
wild type (189 and 137 bp) and mutant (162, 137 + 27 bp
fragments) variants on codon 59 of the gene. Mutation at
this codon reflects substitution of amino acid cystine
(Cys, wild type) by arginine (Arg, mutant).
The M3 + F/ amplified PCR fragments (Figure 1b) were
digested with TSP509I and DraI to distinguish variants at
codon 51 and 164, respectively. Digestion by TSP509I
produced fragments of sizes 153 and 120 bp indicative of
presence of amino acid asparagine (wild type) and 217
and 120 bp indicating presence of amino acid isoleucine
(Ile, mutant). On the other hand, digestion with DraI was
expected to produce fragments of sizes 245, 171 and 106
bp (wild type) and 145, 143, 106 and 28 bp (mutant) dis-
tinguishing polymorphisms at codon 164. In this context
wild type denotes occurrence of isoleucine (Ile) and the
mutant indicates occurrence of leucine (Le). The four
restriction enzymes were used mutually to detect muta-
tions on the dhfr gene ascribed to resistance to antifolate,
SP by the malaria parasite.
Tests for polymorphisms on dhps are shown in Figures 2d
and 2e. PCR products of approximately 438 bp (Figure 1c)
were obtained from amplification with the K and K/ prim-
ers. The variants at codon 437 were discriminated by
restriction digestion using the restriction enzyme AvaII
Agarose gels of the PCR products ((a) F+M4; (b) M3+F/; (c) K+K/; (d) L+L/) of the tests for the polymorphisms of dhf and dhps Figure 1
Agarose gels of the PCR products ((a) F+M4; (b) M3+F/; (c) K+K/; (d) L+L/) of the tests for the polymorphisms of dhf and dhps. 
Fragment sizes are in bp.Malaria Journal 2006, 5:94 http://www.malariajournal.com/content/5/1/94
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(Figure 2d). In this case uncut fragment (438 bp) indi-
cated wild type while mutations at this site was shown by
a cut fragment sized 404+ bp. Mutation at this codon is
indicative of substitution of glycine (Gly) for alanine
(Ala). The K + K/ amplified PCR products have been used
to detect polymorphisms occurring at codon 540. A
restriction enzyme, FokI produced fragments sized 405 bp
(wild type) and 320 and 85 bp (mutant) discriminating
variants at that codon. The 405 bp fragment indicates
presence of amino acid Lysine (Lys) while the 320 and 85
bp fragments reflect substitution of glutamate (Glu) for
lysine at this codon.
Following amplification with L + L/ primers, PCR prod-
ucts of size 161 bp were produced (Figure 1d). These PCR
fragments have been used to describe polymorphism on
the dhps gene occurring at codon 581 using a restriction
enzyme BstUI. This restriction enzyme produced restric-
tion digests of sizes 105, 33 and 23 bp (wild type) and 138
and 23 bp (mutant) from the PCR products of size 161 bp
(Figure 2d). The former reflects presence of amino acid,
alanine at this codon and the latter indicates substitution
of glycine for alanine.
Mutation analysis was variably successful at each codon in
both dhfr and dhps genes and an average of 120 (85.1%)
of 141 patients produced fruitful outcome. Four codons
(51, 59, 108 and 164) on dhfr and three codons (437, 540
and 581) on dhps were evaluated and the results are pre-
sented in Figures 2. Mutations in the dhfr were highest for
Asn-108 (66.9%) and progressively declined for dhfr Ile-
51 (62.7%) and dhfr Arg-59 (48.8%). Mutations in dhps
Polyacrylamide gels of the restriction digest of the PCR products ((a)AluI and xmnI; (b) AluI and xmnI; (c)TSP609I and DraI; (d)  BSTUI and AvaII; (e) FokI) of the tests for the polymorphisms of the dhfr and dhps genes Figure 2
Polyacrylamide gels of the restriction digest of the PCR products ((a)AluI and xmnI; (b) AluI and xmnI; (c)TSP609I and DraI; (d) 
BSTUI and AvaII; (e) FokI) of the tests for the polymorphisms of the dhfr and dhps genes. Fragment sizes are in bp.Malaria Journal 2006, 5:94 http://www.malariajournal.com/content/5/1/94
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varied from dhps Gly-437 (43.7%), dhps Glu-540 (39.2%)
and was lowest for dhps Gly-581 (0.8%) alleles. In all pre-
treatment and post-treatment samples, no mutant dhfr
Leu-164 was depicted. The triple dhfr, double dhps and the
quintuple mutants (carrying the dhfr triple mutant and
the dhps double mutant) were also evaluated and were
considerable (Table 3). Mixed pattern was not uncom-
mon in many samples examined (Table 4).
Discussion
The 141 patients represent children aged less than five
years, the age most vulnerable to falciparum malaria [26].
Parasite recurrence in SP treated individuals has been
linked to many factors. Such factors include overwhelmed
immunity, multiple concurrent infections and drug resist-
ance [27]. Several previous studies have investigated the
association between mutations in dhfr and dhps and the
parasitological and/or clinical response to SP medication
at individual level [6,28-30]. Most of these studies pro-
duced tangible results regarding the use of dhfr and dhps
genotypes as resistance marker genes for SP [31]. In this
study, it was observed (clinical data) that SP treatment
cleared infection in 89.4% of the patients who completed
the study. This treatment success is partly concordant but
higher than what has previously been reported (82%) in a
similar study by Aubouy et al. [25] in Bakoumba village in
Haut-Ogooué province of Southeast Gabon. According to
that study, dhfr mutations that lead to high-level in vitro
resistance to pyrimethamine plus one or two dhps muta-
tions were reported to be not sufficient to induce in vivo
failure of SP treatment in young children. Nevertheless,
the semi-immune population of over 60% previously
reported in Tanzania [32] is probable reminiscent for the
observed high parasite clearance despite detection of high
resistance-associated point mutations in this study.
Slightly higher values of mutations on dhfr (66.9% and
62.7%) were detected at codons 108 and 51, respectively
as compared to those previously reported by Mshinda
[33] of 50%. This is attributable to rapid, stepwise selec-
tion of mutations following use of antimalarial, SP or sim-
ilar drugs in the area. This is simply because our study was
carried 2 years after a similar study by Mshinda in 2000.
Pharmacological case management of the disease occur-
ring at informal level [26,34] with poor compliance with
dosing schedules could be another basis for the high fre-
quency of mutations detected in this study. In addition,
sub-dosage levels of drug administration e.g. two patients
sharing a single dose prescribed for a single patient (per-
sonal observation) may be a probable cause for the
detected high proportion of mutations. Extensive use of
different types of antifolates with mechanism of action
similar to SP like trimethoprim and sulphamethoxazole
(TS) combination (e.g. septrin) in treating other infec-
tions over time, probably accounts for the increased selec-
tion of mutations ascribed to SP resistance [17].
The mutation of about 66.9% observed in dhfr on codon
108 was higher than that reported by Jelinek et al. [35] in
West Africa (54.0%) but slightly lower than that observed
in Central Africa (72.4%), South Africa (68.9%) and East
Africa (72.9%). This could be correlated to the high pro-
portion of mixed genotype infections (mutant and wild
type, 19.0%) detected at this codon in the present study.
Pearce et al. [17] reported the increase of mixed genotypes
in codons whose mutations are associated with SP resist-
ance in an area of high endemicity. This proportion of
mixed genotypes could give rise to dhfr  mutations of
about 85.9% if at all these genotypes were additive. The
dhfr point mutations at codons 51 and 59 were also higher
than that previously reported by Jelinek et al. [35] in
Africa and all together explains the significance of these
mutations in causing higher SP resistance. As previously
reported by Hastings et al. [36], mutations at codon 164
in dhfr, which is thought to confer highest SP resistance
when it occurs, was not depicted in this study. Generally,
mutations in the three codons in the dhfr domain were
higher (Table 2) than those on the dhps domain, suggest-
ing that mutations on dhfr precede those on dhps in con-
ferring parasite resistance to SP [37].
The point mutations in dhps depicted in this study are far
higher than what was observed in previous studies in East
and South Africa [35] and Eastern Iran [38]. This might be
explained by the widespread use of septrin in Tanzania,
which is said to indirectly select mutations for SP resist-
Table 2: Proportions of point mutations on dhfr and dhps related to parasite resistance to antifolates
Resistance to Gene locus Mutations (%) Wild type (%) Mixed (%) Total
Pyrimethamine DHFR 51 74 (62.7%) 35 (29.7%) 9 (7.6%) 118
DHFR 59 59 (48.8%) 36 (29.8%) 26 (21.5%) 121
DHFR 108 81 (66.9%) 17 (14.1%) 23 (19.0%) 121
DHFR 164 0 (0.0%) 104 (100.0%) 0 (0.0%) 104
Sulphadoxine DHPS 437 56 (43.7%) 71 (55.5%) 1 (0.8%) 128
DHPS 540 47 (39.2%) 65 (54.5%) 8 (6.3%) 120
DHPS 581 1 (0.8%) 126 (98.4%) 1 (0.8%) 128
318 454 68 840Malaria Journal 2006, 5:94 http://www.malariajournal.com/content/5/1/94
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ance [17]. Takahashi et al. [39] further reported that the
use of antifolates such as co-trimoxazole for prophylaxis
or medication against other infections than malaria indi-
rectly and predominantly select double mutations at dhps
for resistance. Nevertheless, the dhps mutations observed
in this study were relatively lower than that observed in
Central and West Africa by Jelinek et al. [35], possibly due
to geographical differences [16] and differences in pat-
terns of drug use between different areas [17]. However,
Beswas [16] reported the dhps  mutations in Tanzania
ranging between 30 – 34%, which is less than values
observed in our study (39.2 – 43.7%) signifying that drug
pressure increasingly selects these mutant alleles with
time depending on frequent use of antifolates.
Overall proportion of point mutations portrayed in this
study reflects the existence of high resistance in the study
area. Only 8.5% of infections carried pure wild type geno-
type and 4.6% of the samples showed single mutant alle-
les. Quintuple mutations were highest (18.5%) followed
by triple (16.2%) and double mutations (13.8%). Quad-
ruple mutations occurred in 6.9% of samples. About 41
(31.5%) of infections had at least one mixed (mutant,
wild type) genotypes attributable to endemicity of the dis-
ease [40], which may result into high transmission conse-
quently augmenting high proportion of mixed clones per
infection in the population.
The co-occurrence of point mutations in both dhfr and
dhps loci was also examined in this study (Table 3) with
about 44 (36.4%) of samples containing triple mutant on
dhfr, which was relatively similar to that reported by
Mshinda [33] in the same place (41%) but was almost
twice to values reported by Mugittu et al. [15] of 18.6%.
However, the proportion could escalate if the mixed triple
dhfr variants (22.1%) and mixed double dhfr variants 16
(23.53%) detected in the present study (Table 4) were
counted inclusively. Nevertheless, the proportion of these
mutations was less than that reported by Pearce et al. [17]
in Hai district Northern Tanzania (>70%) where resist-
ance to SP is already unprecedentedly high due to wide-
spread use of SP and spread of resistance from nearby
area, Muheza into the area. Mugittu et al. [15] reported a
prevalence of 80.3% in Mkuzi, an area in Muheza District
where pyrimethamine was used for prophylactic and/or
therapeutic trials at different periods from 1950s to 1994
[41-43]. The difference in levels of SP resistance between
Tanzanian communities is also attributable to the differ-
Table 4: Proportions of mixed infections detected in this study
Category Variants detected Total No. of variants Percentage (%)
smDHFR 27 × 1 27 39.7
smDHPS 8 × 1 8 11.8
dmDHFR 8 × 2 16 23.5
dmDHPS 1 × 2 2 2.9
tmDHFR 5 × 3 15 22.1
tmDHPS 0 × 3 0 0.00
Total 68 100
smDHFR = Mixed variants detected at a single codon on the dhfr domain; mDHPS = Mixed variants detected at a single codon on the dhps domain; 
dmDHFR = Mixed variants detected at two codons on the dhfr domain; dmDHPS = Mixed variants detected at two codons on the dhps domain; 
tmDHFR = Mixed variants detected at three codons on the dhfr domain; tmDHPS = Mixed variants detected at three codons on the dhps domain
Table 3: Various dhfr/dhps combinations obtained from restriction analysis to determine point mutations in genes responsible for SP 
resistance.
Category Number Percentage (%) Percent Cum.
tDHFR 44 36.40 36.40
dDHPS 18 14.90 51.30
tDHFR/dDHPS 24 19.80 71.10
dDHFR/dDHPS 10 8.30 79.40
tDHFR/sDHPS 4 3.30 82.70
dDHFR/sDHPS 7 5.80 88.50
tDHFR/nDHPS 14 11.50 100.00
Total 121 100.0
tDHFR = Triple mutants on dhfr gene; dDHFR = Double mutants on dhfr gene; dDHPS = Double mutants on the dhps gene; sDHPS = Single mutant 
on the dhps gene; nDHPS = No mutation on the dhps geneMalaria Journal 2006, 5:94 http://www.malariajournal.com/content/5/1/94
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ences in patterns of drug use between communities within
the country [17]. In Muheza District Hospital, for
instance, SP was implemented as first-line drug in chil-
dren less than 5 years of age since 1984 [44].
The frequency of triple-dhfr/double-dhps mutants (quintu-
ple mutation, 19.8%) depicted (Table 3) is high as com-
pared to previous studies in Mlimba and Idete [45] which
was reported as a rare event. However, the proportion of
quintuple mutation in Mlimba was less than that reported
by Pearce et al. [17] in Hai and Pare areas of Northern
Tanzania (30 – 63%). The proportion of quintuple muta-
tion was also less than that generally reported by Jelinek
et al. [35] (42.9%) in East Africa, and that by Bwijo et al.
[46] in Maonga and Chimbala villages of Salima District,
Malawi (78%). The lower frequency of quintuple muta-
tions (19.8%) observed in this study as compared to other
reported mutations in Tanzania and other areas of Africa
could partly be attributable to the early development of
resistance in those areas. In Malawi for instance, the study
was carried 7 years after introduction of SP as a first-line
drug while our study was carried shortly (2 years) after
introduction of SP as an interim first-line drug in Tanza-
nia, providing a relatively shorter time for selection of SP
resistance mutations. In addition the low quintuple muta-
tions can also be linked to the proportion of genotypes at
similar locus possessing mixed variants observed in this
study. In previous studies, the mixed variants were not
reported. The random selection of these mutations might
generally, be a consequent of country-wide use of SP as a
second-line antimalarial drug several years before it was
implemented as an interim first-line drug by August 2001.
The prevalence of double dhps mutation (Table 3), which
is considered to be a prerequisite for resistance to sul-
phonamides [7], was found to be 6× that reported by
Mugittu et al. [15] in the same area. This proportion
(19.8%) was also higher than that reported in Kyela and
Masasi areas of Tanzania but nearly equal to that reported
in Butimba but less than that reported in Mkuzi areas of
Tanzania by Mugittu et al. This might be attributed to the
effect of septrin, an antifolate extensively used in Tanzania
as antibiotic agent, indirectly and preferentially selecting
double mutations on the dhps locus [39]. Similar effects
can result from septrin, which is essentially similar to co-
trimoxazole in composition as previously stated. Both are
antifolates basically composed of trimethoprim-sulpham-
ethoxazole (TS) with similar effects to SP [46,47]. Obser-
vation also showed that 52.1% of infections harboured at
least one mutation on the dhps locus (Table 3) reflecting
that probably there is high effect or prevailing use of sep-
trin in the area. This can also be associated with long-term
abuse of the drug, but also could be indicative of the dif-
ferences in the generic drugs available in the country man-
ufactured by different companies which might have
different bioavailability and therapeutic values. The high
proportion of double dhps mutations when coupled with
triple mutations in dhfr can result into quintuple muta-
tion to confer highest SP resistance.
Mixed genotypes in either dhfr  or  dhps, or both, were
depicted in at least 68 DNA samples (Table 4). Detection
of mixed genotypes in dhfr and dhps is important due to
its influence on the overall proportion of point mutations
in baseline samples which upon drug pressure, the wild
type get cleared with mutant genotypes persisting in lon-
gitudinal follow up samples. Most recrudescent infection
detected in follow up cases came from pure mutant and
mixed genotypes in baseline samples as parasites with
wild type genotypes are sensitive and were subsequently
cleared post-medication by the drug. The variable results
obtained following PCR-RFLP of follow up samples
(20%) have been previously observed [25]. Infection
detected during follow-up may be either an infection that
previously failed to express due to presence of an abun-
dant (detected) strain that masked the presence of minor
resistant strain, thus being a recrudescent parasite. But on
the other hand the detected mutant alleles during follow-
up may be new infection with similar genotype as that
detected pre-treatment.
Conclusions and recommendations
In conclusions, the impact of quintuple mutation on SP
resistance may be weighed down by host immunity in
endemic areas although may not suggest continued use of
the drug for treatment of malaria. The impact of other
drugs with similar mechanisms of action used as antibiot-
ics in selecting mutations responsible for SP resistance
need be studied especially for co-trimoxazole, which is
currently used as a prophylaxis against opportunistic
infections in HIV-infected individuals. The information
obtained in the present study will be of direct and imme-
diate relevance to current HIV and malaria control poli-
cies in Tanzania and possibly in Africa and the universe.
In addition, it will add to our basic knowledge of the
molecular basis of antifolate-resistant malaria. There is a
need for reviewing the policy on the use of SP as a first-
line drug for treating malaria in Tanzania. In addition,
despite several previous studies showing SP + Amodi-
aquin (SP+AQ) and SP+Artesunate (SP+AS) to cause a
delay in emergence of resistance and rapid gametocyte
clearance, the high SP resistance potential detected in this
study suggests exclusion of SP component in future
planned drug combinations for treatment of malaria.
Alternative combination therapies like artemisinin-based
drugs (e.g. artemisinin-lumefantrine) and short-acting
antimalarials such as chlorproguanil-dapsone combina-
tion (LapDap) and atovaquone-proguanil (Malarone®)
may be rewarding albeit thorough clinical trials are still
needed to evaluate the effectiveness and possible harmfulMalaria Journal 2006, 5:94 http://www.malariajournal.com/content/5/1/94
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side effects of these proposed drugs. In deployment of a
new antimalarial drug for treating malaria, the effect of
other drugs with similar mode of action to drug, used in
treating other infections than malaria have to be consid-
ered to preclude the possibilities of early development of
resistance to the target drug due to cross-resistance. The
findings from this study imply that in vivo studies be fur-
ther carried out to confirm that the high frequency of SP
resistance alleles is indicative of treatment failure.
Improvement of health services with adequate drugs and
skilled medical staffs from village levels may reduce
uncontrolled and inappropriate use of the drug, conse-
quently reducing the chances of selecting SP resistance
mutations against malaria.
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